Start antiplatelet monotherapy — Competitive Intelligence Brief

Start antiplatelet monotherapy (Start antiplatelet monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

phase 3 Antiplatelet agent Cardiovascular Small molecule

Target snapshot

Start antiplatelet monotherapy (Start antiplatelet monotherapy) — The George Institute for Global Health, China. Antiplatelet monotherapy reduces blood clot formation by inhibiting platelet aggregation through a single antiplatelet agent.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Start antiplatelet monotherapy TARGET	Start antiplatelet monotherapy	The George Institute for Global Health, China	phase 3	Antiplatelet agent
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Cilostazol+Probucol	Cilostazol+Probucol	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol)
Single antiplatelet therapy	Single antiplatelet therapy	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent
Ligustrazine by mouth	Ligustrazine by mouth	Shenzhen Kangning Hospital	marketed	Antiplatelet agent / Vasodilator
Clopidogrel loading	Clopidogrel loading	Azienda Policlinico Umberto I	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

1. Asan Medical Center · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
5. China National Center for Cardiovascular Diseases · 1 drug in this class
6. Hospital Israelita Albert Einstein · 1 drug in this class
7. Icahn School of Medicine at Mount Sinai · 1 drug in this class
8. PLx Pharma · 1 drug in this class
9. Sichuan Provincial People's Hospital · 1 drug in this class
10. The George Institute for Global Health, China · 1 drug in this class